Valiglurax, also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson’s disease.

1976050-09-5

C16H10F3N5

329.28

VU-2957;VU0652957;VU2957;VU 2957;VU-0652957;VU 0652957;Valiglurax

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years